In the tumor immune microenvironment with abundant CD8+ T and NK cells, low expression of Treg and M2 macrophages, and high expression of PD1, combined anti-PD1 may be more beneficial in HCC patients. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.